<DOC>
	<DOCNO>NCT01969409</DOCNO>
	<brief_summary>Recent research study suggest protein call antibody produce immune system might involve lung damage idiopathic pulmonary fibrosis ( IPF ) . Antibodies produce immune system normal help fight infection attack bacteria virus without harm tissue . In patient IPF , evidence certain antibody ( call autoantibody ) attack lung contributes injury scar occurs IPF . Our recent study find many IPF patient appear excessive autoantibody level blood lung might make disease bad . Rituximab medication approve Food Drug Administration ( FDA ) treatment autoantibody diseases rheumatoid arthritis . Rituximab work destroy B cell , type white blood cell , call B-lymphocyte , produce autoantibody . In research study , rituximab give vein reduce autoantibody level believe might contribute lung damage IPF . This study conduct determine rituximab provide beneficial effect IPF patient decrease lung injury .</brief_summary>
	<brief_title>Autoantibody Reduction Therapy Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>This double-blinded , Phase II trial 58 ambulatory IPF patient four medical center ( University Pittsburgh , University Chicago , Geisinger Medical Center , Temple University ) randomize equally 1. placebo 2. two dos rituximab 1 gm i.v. , 14 day interval inbetween dos . Subjects follow 9 month .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<criteria>Ambulatory patient diagnosis IPF , establish &gt; 5 year enrollment date , fulfill ATS/ETS Consensus Criteria . Ability willingness give inform consent . Presence autoantibody HEp2 cell , assay primary endpoint . Age 5085 y.o . Diagnoses current infection , proven suspect participate physician base upon clinical assessment . Presence active hepatitis B C , HIV infection . Presence positive CONVENTIONAL autoimmune serologic test , e.g. , ANA , RF , AntiRo , AntiLA , AntiRNP , AntiJo1 . History reaction murinederived product trial medication , prior exposure humanmurine chimeric antibody . Malignancy , exclude basal squamous cell skin cancer lowrisk prostate cancer , define stage T1 T2a PSA le 10 ng/dl . Unwillingness complete posttreatment surveillance 9 month . Diagnosis major morbidity ( aside IPF ) expect interfere subject ' study participation 9 month . Treatment &gt; 5 day within precede month &gt; 10 mg. prednisone ( equivalent corticosteroid ) treatment precede month potent cellular immunosuppressant ( e.g. , cyclophosphomide , methotrexate , mycophenolate , azathioprine , calcineurin inhibitor , etc. ) . Uncontrolled diabetes hypertension preclude safe treatment methylprednisolone . Concurrent participation experimental trial . Pregnancy unwillingness use contraception duration study among female participant childbearing potential . Ratio force expiratory volume 1 second force vital capacity ( FEV1/FVC ) &lt; 70 % predicted value .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Lung</keyword>
	<keyword>Fibrosis</keyword>
</DOC>